Nivolumab FDA approval date

The FDA approved Nivolumab (BMS-936558) on 22 Dec 2014.

FDA approval date
22 Dec 2014

Drug identity checked against registry records

Also recorded as BMS-936558; OPDIVO; Opdivo; Opdivo®

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673ExelixisPhase 3Active not recruiting2026-12-15Estimated
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219ExelixisPhase 3Active not recruiting2022-01-31Actual
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332IDEAYA BiosciencesPhase 2, Phase 3Active not recruiting2027-01-15Estimated
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Replimune, Inc.Phase 3Recruiting2030-09-30Estimated
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314Immunocore LtdPhase 3Recruiting2027-10-16Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574ExelixisPhase 3Enrolling by invitation2030-05-31Estimated
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095RCUSPhase 3Completed2026-08-28Actual
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaNCT06581406Replimune, Inc.Phase 2, Phase 3Recruiting2030-01Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2014-12-22DayNivolumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA125554", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["OPDIVO"], "active_ingredients": ["NIVOLUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20141222", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026